Bio-Rad Laboratories, Inc.
BIO
$305.56
-$0.99-0.32%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.51% | 2.05% | -4.16% | -2.00% | 2.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.51% | 2.05% | -4.16% | -2.00% | 2.78% |
| Cost of Revenue | 5.80% | 8.27% | -3.38% | 3.42% | -1.09% |
| Gross Profit | -3.84% | -2.90% | -4.84% | -6.66% | 6.20% |
| SG&A Expenses | 2.36% | 4.75% | -8.08% | -1.53% | -0.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.22% | 6.32% | -5.47% | 3.98% | 7.90% |
| Operating Income | 3.03% | -20.80% | 10.06% | -38.97% | -27.59% |
| Income Before Tax | -150.03% | 114.86% | -83.02% | -312.17% | 528.44% |
| Income Tax Expenses | -142.80% | 115.50% | -81.90% | -345.49% | 575.64% |
| Earnings from Continuing Operations | -152.34% | 114.68% | -83.33% | -304.67% | 514.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -152.34% | 114.68% | -83.33% | -304.67% | 514.74% |
| EBIT | 3.03% | -20.80% | 10.06% | -38.97% | -27.59% |
| EBITDA | 6.96% | -12.20% | 6.98% | -26.48% | -18.33% |
| EPS Basic | -154.34% | 115.31% | -82.99% | -310.48% | 540.09% |
| Normalized Basic EPS | 9.30% | -21.54% | 12.92% | -36.80% | -29.64% |
| EPS Diluted | -154.41% | 115.30% | -82.97% | -310.69% | 541.21% |
| Normalized Diluted EPS | 9.44% | -21.54% | 12.93% | -36.75% | -29.43% |
| Average Basic Shares Outstanding | -3.67% | -4.12% | -2.02% | -2.76% | -3.96% |
| Average Diluted Shares Outstanding | -3.79% | -4.11% | -2.04% | -2.84% | -4.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |